Can we really protect the ovary from chemotherapy damage?
- PMID: 40120392
- DOI: 10.1016/j.bpobgyn.2025.102603
Can we really protect the ovary from chemotherapy damage?
Abstract
Future alternatives to current fertility preservation methods such as pharmacological strategies to prevent chemotherapy-induced ovarian damage in female cancer patients are of growing interest. Chemotherapeutic agents, especially alkylating agents, cause DNA damage and apoptosis in ovarian follicles, significantly reducing ovarian reserve. To mitigate this gonadotoxicity, various emerging strategies are being explored, including kinase inhibitors, PI3K/Akt/mTOR pathway inhibitors, antioxidants, miRNAs and GnRH agonists. These treatments work by preventing follicular apoptosis or excessive activation of primordial follicles. Although promising results have been observed in vitro and in vivo in rodent models, further investigations to bypass their limitations are needed to confirm their efficacy and safety. These challenges include the non-interference with anti-tumoral effect of chemotherapy and the specificity of fertoprotective agents to ovaries.
Keywords: Chemotherapy; Fertility preservation; Ovary; Pharmacoprotection.
Copyright © 2025. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of competing interest The manuscript was supported by the Fonds National de la Recherche Scientifique (FNRS-PDR). Isabelle Demeestere is senior researcher at FNRS. The authors have no conflict of interest to declare related to this work.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
